126 related articles for article (PubMed ID: 27645108)
1. Challenges in studying very rare cancer outcomes and infrequent exposures: example of teriparatide and osteosarcoma.
Andrews EB; Gilsenan A; Midkiff K; Harris D
Ann Epidemiol; 2016 Nov; 26(11):751-753. PubMed ID: 27645108
[No Abstract] [Full Text] [Related]
2. Safety of parathyroid hormone for the treatment of osteoporosis.
Miller PD
Curr Osteoporos Rep; 2008 Mar; 6(1):12-6. PubMed ID: 18430395
[TBL] [Abstract][Full Text] [Related]
3. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years.
Andrews EB; Gilsenan AW; Midkiff K; Sherrill B; Wu Y; Mann BH; Masica D
J Bone Miner Res; 2012 Dec; 27(12):2429-37. PubMed ID: 22991313
[TBL] [Abstract][Full Text] [Related]
4. Safety of osteoanabolic therapy: a decade of experience.
Cipriani C; Irani D; Bilezikian JP
J Bone Miner Res; 2012 Dec; 27(12):2419-28. PubMed ID: 23165426
[No Abstract] [Full Text] [Related]
5. Recombinant human parathyroid hormone. Preclinical data on rat osteosarcoma were not dismissed.
Kuijpers G; Schneider B; Stadel B; Colman E
BMJ; 2002 May; 324(7347):1218; author reply 1218. PubMed ID: 12016199
[No Abstract] [Full Text] [Related]
6. Probable osteosarcoma risk after prolonged teriparatide treatment: comment on the article by Saag et al.
Tastekin N; Zateri C
Arthritis Rheum; 2010 Jun; 62(6):1837; author reply 1837-8. PubMed ID: 20191586
[No Abstract] [Full Text] [Related]
7. Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis.
Hodsman A; ; Papaioannou A; ; Ann Cranney ;
CMAJ; 2006 Jul; 175(1):48. PubMed ID: 16818909
[No Abstract] [Full Text] [Related]
8. Osteosarcoma and teriparatide?
Harper KD; Krege JH; Marcus R; Mitlak BH
J Bone Miner Res; 2007 Feb; 22(2):334. PubMed ID: 17129179
[No Abstract] [Full Text] [Related]
9. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.
Orwoll ES; Scheele WH; Paul S; Adami S; Syversen U; Diez-Perez A; Kaufman JM; Clancy AD; Gaich GA
J Bone Miner Res; 2003 Jan; 18(1):9-17. PubMed ID: 12510800
[TBL] [Abstract][Full Text] [Related]
10. Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34)).
Watanabe A; Yoneyama S; Nakajima M; Sato N; Takao-Kawabata R; Isogai Y; Sakurai-Tanikawa A; Higuchi K; Shimoi A; Yamatoya H; Yoshida K; Kohira T
J Toxicol Sci; 2012; 37(3):617-29. PubMed ID: 22688001
[TBL] [Abstract][Full Text] [Related]
11. Of mice and men: divergent risks of teriparatide-induced osteosarcoma.
Subbiah V; Madsen VS; Raymond AK; Benjamin RS; Ludwig JA
Osteoporos Int; 2010 Jun; 21(6):1041-5. PubMed ID: 19597911
[TBL] [Abstract][Full Text] [Related]
12. Teriparatide for postmenopausal osteoporosis.
Drug Ther Bull; 2004 Dec; 42(12):93-5. PubMed ID: 15587764
[TBL] [Abstract][Full Text] [Related]
13. Osteosarcoma risk in rats using PTH 1-34.
Barbehenn EK; Lurie P; Wolfe SM
Trends Endocrinol Metab; 2001 Nov; 12(9):383. PubMed ID: 11595538
[No Abstract] [Full Text] [Related]
14. Parathyroid hormone as a therapeutic agent.
Mitlak BH
Curr Opin Pharmacol; 2002 Dec; 2(6):694-9. PubMed ID: 12482733
[TBL] [Abstract][Full Text] [Related]
15. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
Brixen KT; Christensen PM; Ejersted C; Langdahl BL
Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
[TBL] [Abstract][Full Text] [Related]
16. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.
Hodsman AB; Bauer DC; Dempster DW; Dian L; Hanley DA; Harris ST; Kendler DL; McClung MR; Miller PD; Olszynski WP; Orwoll E; Yuen CK
Endocr Rev; 2005 Aug; 26(5):688-703. PubMed ID: 15769903
[TBL] [Abstract][Full Text] [Related]
17. Treatment of osteoporosis with parathyroid hormone and teriparatide.
Pleiner-Duxneuner J; Zwettler E; Paschalis E; Roschger P; Nell-Duxneuner V; Klaushofer K
Calcif Tissue Int; 2009 Mar; 84(3):159-70. PubMed ID: 19189037
[TBL] [Abstract][Full Text] [Related]
18. Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study.
Gilsenan A; Midkiff K; Harris D; Kellier-Steele N; McSorley D; Andrews EB
J Bone Miner Res; 2021 Feb; 36(2):244-251. PubMed ID: 32990990
[TBL] [Abstract][Full Text] [Related]
19. Assessing the incidence of osteosarcoma among teriparatide-treated patients using linkage of commercial pharmacy and state cancer registry data, contributing to the removal of boxed warning and other labeling changes.
Kellier-Steele N; Casso D; Anderson A; Oliveria SA; Motsko S
Bone; 2022 Jul; 160():116394. PubMed ID: 35318162
[TBL] [Abstract][Full Text] [Related]
20. Teriparatide. LY 333334, MN 10T, parathyroid hormone (1-34), parathyroid hormone (1-34)-Asahi, parathyroid hormone (1-34)-Eli Lilly, parathyroid hormone (1-34)-Rhône-Poulenc Rorer, teriparatide acetate, hPTH 1-34, Parathar.
Drugs R D; 1999 Mar; 1(3):222-4. PubMed ID: 10566031
[No Abstract] [Full Text] [Related]
[Next] [New Search]
